InterVenn BioSciences

Executive Summary

InterVenn BioSciences is a clinical-stage diagnostics company pioneering glycoproteomics-based liquid biopsy tests for precision oncology. Founded in 2017 and headquartered in South San Francisco, the company leverages its proprietary GlycoVision platform, which integrates artificial intelligence with high-resolution mass spectrometry to decode the glycoproteome—the complete set of glycoproteins in a biological sample. By analyzing glycosylation patterns, InterVenn aims to detect cancer earlier, monitor disease progression, and predict therapeutic responses with high specificity and sensitivity. Its lead candidate targets ovarian cancer detection, with additional programs in lung and colorectal cancers. The company's approach addresses a critical gap in current diagnostics, as glycoproteomic biomarkers offer unique insights into disease biology not captured by genomics or proteomics alone. InterVenn has generated promising early clinical data demonstrating its test's ability to differentiate malignant from benign ovarian masses with superior accuracy compared to existing standards. The company is now advancing larger validation studies and engaging with strategic partners to accelerate commercialization. With a strong intellectual property portfolio and a growing body of clinical evidence, InterVenn is well-positioned to become a leader in liquid biopsy diagnostics. Key upcoming milestones include the completion of a pivotal study for ovarian cancer, potential collaborations with pharmaceutical companies for companion diagnostics, and an initial regulatory submission to the FDA. Successful execution of these catalysts could validate the platform's broad utility and drive significant value inflection.

Upcoming Catalysts (preview)

• Q4 2026Pivotal study data readout for ovarian cancer liquid biopsy test70% success
• Q2 2027Pharmaceutical partnership for companion diagnostic development50% success
• Q3 2027FDA submission for first test40% success